Humanized Anti-CD70 Binding Agents and Uses Thereof
AssigneeSeagen Inc.
InventorsCharlotte McDonagh, Paul Carter
Life of this patent
Estimating the term…
Abstract
Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
Claims18
An antibody or antigen-binding fragment thereof that specifically binds to human CD70, comprising a humanized heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of the human germline VH1-2 or VH1-18.
10-22. (canceled)
26-32. (canceled)
36-38. (canceled)
Dependencies are inferred from the claim text.